Decreasing overall 5-HT levels using the non-selective inhibitor of both central and peripheral TPH (PCPA), was shown to reduce obesity and adiposity, as well as diet- and alcohol-induced hepatic steatosis and inflammation 198,219,224,225,304,339. This evidence concerns the gene TPH1 and fatty liver disease.